Marta Biondi
Research Subjects
Marta Biondi has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Biondi
School of Medicine and Surgery University of Milano‐Bicocca Monza MB Italy
2 shared publications - Marta Serafini
Tettamanti Center and Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
2 shared publications Alice Pievani
Tettamanti Center and Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
1 shared publication- Alice Pievani
Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
1 shared publication Andrea Lia
Institute of Nanotechnology (NANOTEC), National Research Council of Italy (CNR), Campus Ecotekne, Via Monteroni, 73100 Lecce, Italy
1 shared publication- Antonio Galeone
Institute of Nanotechnology, National Research Council (CNR-NANOTEC), Lecce, 73100, Italy, Tecnomed Puglia - Tecnopolo per la medicina di precisione (Biotech Lecce Hub), 73100 Lecce, Italy
1 shared publication
Latest Publications
- Open Access
Differential TIM-3 glycosylation enables specific dual targeting CAR-T therapy in acute myeloid leukemia
Chimeric Antigen Receptor (CAR) therapy for Acute Myeloid Leukemia (AML) is hindered by disease heterogeneity, antigen overlap with normal hematopoiesis, and the persistence of leukemic stem cells (LSCs). To overcome these barriers, we employed the IF-BETTER strategy to simultaneously target CD33 and the LSC-associated marker TIM-3 by pairing a second-generation CAR with a Cytokine-Costimulatory Receptor (CCR) in two dual CAR configurations (CD33.CAR/TIM-3.CCR and TIM-3.CAR/CD33.CCR). Both constructs displayed potent antigen-restricted cytotoxicity against AML cell lines and primary blasts, achieving leukemia clearance, while sparing normal immune and hematopoietic cells. Mechanistic studies revealed that the TIM-3.CAR single-chain fragment variable (scFv) recognizes a protein-proximal epitope whose interaction is selectively enhanced by AML-specific hyper-fucosylated and hyper-sialylated N-glycans. Fucosylation blockade reduced TIM-3.CAR avidity and cytotoxicity, confirming a glycosylation-modulated interaction. Integrating this glycosylation-tolerant TIM-3 scFv into a dual CAR framework enables selective targeting of AML cells, providing a rational strategy for safer and more effective AML-directed immunotherapy.
Open AccessDifferential TIM-3 glycosylation enables specific dual targeting CAR-T therapy in acute myeloid leukemia
Chimeric Antigen Receptor (CAR) therapy for Acute Myeloid Leukemia (AML) is hindered by disease heterogeneity, antigen overlap with normal hematopoiesis, and the persistence of leukemic stem cells (LSCs). To overcome these barriers, we employed the IF-BETTER strategy to simultaneously target CD33 and the LSC-associated marker TIM-3 by pairing a second-generation CAR with a Cytokine-Costimulatory Receptor (CCR) in two dual CAR configurations (CD33.CAR/TIM-3.CCR and TIM-3.CAR/CD33.CCR). Both constructs displayed potent antigen-restricted cytotoxicity against AML cell lines and primary blasts, achieving leukemia clearance, while sparing normal immune and hematopoietic cells. Mechanistic studies revealed that the TIM-3.CAR single-chain fragment variable (scFv) recognizes a protein-proximal epitope whose interaction is selectively enhanced by AML-specific hyper-fucosylated and hyper-sialylated N-glycans. Fucosylation blockade reduced TIM-3.CAR avidity and cytotoxicity, confirming a glycosylation-modulated interaction. Integrating this glycosylation-tolerant TIM-3 scFv into a dual CAR framework enables selective targeting of AML cells, providing a rational strategy for safer and more effective AML-directed immunotherapy.
- Open Access
- 31 January 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (1) , e008275
CARs are sharpening their weapons
The tumor microenvironment hinders CAR T-cell access, activation, and persistence at the tumor site, thereby impacting on the therapeutic efficacy. To tackle these obstacles, ongoing efforts are focusing on further engineering CAR T-cells to enhance their homing, fitness, long-term persistence, and antitumor activity. Advances in genetic modification have prompted the development of armored CAR T-cells equipped with a combination of synergistic elements strengthening their function. These include cytokine release, chemokine receptor expression, immune checkpoint inhibition, gene-editing of inhibitory molecules, or metabolic reprogramming, among others. Multiarmored CAR T-cells may allow addressing the unmet clinical needs of patients with solid tumors or hard-to-treat hematological malignancies who do not benefit from conventional CAR T-cell therapy. Accordingly, several clinical trials are currently assessing the safety and efficacy of these novel CAR constructs.
- 31 January 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (1) , e008275
Open AccessCARs are sharpening their weapons
The tumor microenvironment hinders CAR T-cell access, activation, and persistence at the tumor site, thereby impacting on the therapeutic efficacy. To tackle these obstacles, ongoing efforts are focusing on further engineering CAR T-cells to enhance their homing, fitness, long-term persistence, and antitumor activity. Advances in genetic modification have prompted the development of armored CAR T-cells equipped with a combination of synergistic elements strengthening their function. These include cytokine release, chemokine receptor expression, immune checkpoint inhibition, gene-editing of inhibitory molecules, or metabolic reprogramming, among others. Multiarmored CAR T-cells may allow addressing the unmet clinical needs of patients with solid tumors or hard-to-treat hematological malignancies who do not benefit from conventional CAR T-cell therapy. Accordingly, several clinical trials are currently assessing the safety and efficacy of these novel CAR constructs.